
OMB APPROVAL

OMB Number: 3235-0145
Expires: October 31, 1994
Estimated average burden
hours per response...14.90

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13D/A

Under the Securities Exchange Act of 1934
(Amendment No. 1)

Gish Biomedical, Inc.

(Name of Issuer)

Common Stock, par value \$.01 per share

(Title of Class of Securities)

376360103

(CUSIP Number)

S. Craig Tompkins, Vice Chairman, Citadel Holding Corporation and Craig
Corporation
550 South Hope Street, Suite 1825, Los Angeles, California 90071 (213) 239-0555

(Name, Address and Telephone Number of Person Authorized
to Receive Notices and Communications)

March 8, 1999

(Date of Event which Requires Filing of this Statement)

If the filing person has previously filed a statement on Schedule 13G to report the acquisition which is the subject of this Schedule 13D, and is filing this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g) check the following box. []

Note: Six copies of this statement, including all exhibits, should be filed with the Commission. See Rule 13d-1(a) for other parties to whom copies are to be sent.

*The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

The information required on the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 ("Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Citadel Holding Corporation
95-3885184

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)
(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS*

WC

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

SOLE VOTING POWER

7
NUMBER OF 456,950
SHARES

SHARED VOTING POWER

8
BENEFICIALLY OWNED BY 0
EACH

SOLE DISPOSITIVE POWER

9
REPORTING PERSON 456,950

SHARED DISPOSITIVE POWER

10
WITH 0

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

456,950

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

13.24%

14 TYPE OF REPORTING PERSON*

CO

*SEE INSTRUCTIONS BEFORE FILLING OUT.

1 NAME OF REPORTING PERSON
S.S. OR I.R.S. IDENTIFICATION NO. OF ABOVE PERSON

Craig Corporation
95-1620188

2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*

(a)
(b)

3 SEC USE ONLY

4 SOURCE OF FUNDS*

not applicable

5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED PURSUANT
TO ITEMS 2(d) or 2(e)

6 CITIZENSHIP OR PLACE OF ORGANIZATION

Delaware

SOLE VOTING POWER

7
NUMBER OF SHARES

0

SHARED VOTING POWER

8
BENEFICIALLY OWNED BY

456,950

SOLE DISPOSITIVE POWER

9
EACH REPORTING PERSON

0

SHARED DISPOSITIVE POWER

10
WITH

456,950

11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

456,950

12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*

13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)

13.24%

14 TYPE OF REPORTING PERSON*

CO

*SEE INSTRUCTIONS BEFORE FILLING OUT.

Item 1. Security and Issuer.

This Amendment No. 1 relates to the Schedule 13D filed November 25, 1998 in connection with the ownership by Citadel Holding Corporation, a Delaware corporation ("CHC and collectively with its consolidated subsidiaries, "Citadel") of the Common Stock, no par value (the "Common Stock"), of Gish Biomedical, Inc., a California corporation (the "Issuer") whose principal executive offices are located at 2681 Kelvin Avenue, Irvine, California 92614.

Item 3. Source and Amount of Funds or Other Consideration.

Since the date of the Schedule 13D filing, CHC has acquired 58,100 Shares at the aggregate purchase price of \$155,275.56, including brokerage commissions where applicable. CHC purchased the Shares with CHC's liquid funds on hand. No portion of such funds were borrowed.

Item 5. Interest in Securities of the Issuer.

a) To the best knowledge of CHC, the aggregate amount of securities held by the CHC Parties is 456,950 shares of Common Stock, representing approximately 13.24% of the shares of Common Stock outstanding.

Percentage ownership is based upon the total Shares reported as outstanding in the Company's Form 10-Q for the quarter ended December 31, 1998.

b) All of the shares of Common Stock reported under this Item 5 with respect to the CHC Parties is held by CHC, and CHC has the sole power to vote and dispose of the 456,950 Shares.

c) CHC has engaged within the last sixty days in the following transactions in Common Stock of the Issuer, all of which were effectuated on the Nasdaq National Market.

Date	Number of Shares Purchased	Price per Share/1/
03/02/99	1,600	2.5316
03/04/99	3,800	2.625
03/08/99	52,700	2.625

Total

/1/ Exclusive of brokerage commissions.

Item 7. Material to be Filed as Exhibits.

None

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Dated: March 11, 1999

CITADEL HOLDING CORPORATION
a Delaware corporation

By: /s/ S. Craig Tompkins

S. Craig Tompkins
Vice Chairman

CRAIG CORPORATION
a Delaware corporation

By: /s/ S. Craig Tompkins

S. Craig Tompkins
President